Form 4: BioCorRx Inc. Director Granted Stock Options

Director Brady James Granier received fully vested stock options for 16,698 shares of BioCorRx Inc. on March 28, 2024.

Summary

• On March 28, 2024, Brady James Granier, a director of BioCorRx Inc., was granted stock options.
• The options are for 16,698 shares of common stock.
• The exercise price of the options is $0.90.
• The options were 100% vested upon issuance.
• The options expire on March 28, 2029.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. The sentiment is slightly positive as it indicates alignment of the director's interests with shareholders.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The immediate vesting of the options could incentivize the director to contribute to the company's success in the near term.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotechnology sector.
• The size of the grant (16,698 shares) would need to be compared to grants made to directors at comparable companies to assess its relative value.
• Companies like Amgen, Gilead, and Biogen often use stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting ownership if the options are exercised.
• The grant incentivizes the director, which could benefit the company and its stakeholders.

Key Dates

Keywords

stock options, director, BioCorRx Inc., BICX, Form 4, insider trading